Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:CPHNYSE:HEXONYSE:NINECVE:RX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHCipher PharmaceuticalsC$13.20-5.1%C$12.39C$8.01▼C$19.69C$236.98M1.233,416 shs48,265 shsHEXOHEXO$0.71+2.5%$0.87$0.66▼$3.84$31.24M1.35880,508 shs305,500 shsNINENine Energy Service$0.70+2.9%$0.97$0.60▼$2.02$29.56M2.8948,183 shs914,099 shsRXBioSyentC$10.88+0.3%C$10.75C$8.24▼C$12.13C$124.44M0.934,364 shs2,751 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHCipher Pharmaceuticals0.00%-4.46%+26.00%+5.62%+50.38%HEXOHEXO0.00%0.00%0.00%0.00%0.00%NINENine Energy Service0.00%-23.15%-16.21%-42.73%-64.09%RXBioSyent0.00%-0.91%+4.73%-2.25%+27.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHCipher Pharmaceuticals1.3163 of 5 stars2.40.00.00.00.92.51.3HEXOHEXON/AN/AN/AN/AN/AN/AN/AN/ANINENine Energy Service0.9057 of 5 stars0.04.00.00.01.81.70.6RXBioSyentN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHCipher Pharmaceuticals 2.75Moderate BuyC$14.7511.74% UpsideHEXOHEXO 0.00N/AN/AN/ANINENine Energy Service 0.00N/AN/AN/ARXBioSyent 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CPH, HEXO, NINE, and RX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/7/2025CPHCipher PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetHoldC$12.50(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHCipher PharmaceuticalsC$19.03M12.45C$3.74 per share3.53C$3.96 per share3.33HEXOHEXO$146.20M0.21N/AN/A$2.44 per share0.29NINENine Energy Service$554.10M0.05$0.53 per share1.32($1.01) per share-0.69RXBioSyentC$34.06M3.65C$3.54 per share3.07C$3.22 per share3.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHCipher PharmaceuticalsC$11.41MC$0.9114.58∞N/A59.92%17.93%7.90%N/AHEXOHEXO-$845.90M-$5.21N/AN/AN/A-235.33%-74.04%-32.51%N/ANINENine Energy Service-$32.21M-$1.06N/AN/AN/A-7.64%N/A-11.22%N/ARXBioSyentC$7.02MC$0.6217.66∞N/A20.60%20.01%12.86%N/ALatest CPH, HEXO, NINE, and RX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025NINENine Energy Service-$0.20-$0.18+$0.02-$0.18$149.10 million$150.47 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHCipher PharmaceuticalsN/AN/AN/AN/AN/AHEXOHEXON/AN/AN/AN/AN/ANINENine Energy ServiceN/AN/AN/AN/AN/ARXBioSyentC$0.181.65%N/A29.21%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHCipher Pharmaceuticals41.222.002.67HEXOHEXO0.010.410.24NINENine Energy ServiceN/A2.461.59RXBioSyent2.903.926.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHCipher Pharmaceuticals1.38%HEXOHEXO7.78%NINENine Energy Service57.61%RXBioSyent1.37%Insider OwnershipCompanyInsider OwnershipCPHCipher Pharmaceuticals42.00%HEXOHEXO4.69%NINENine Energy Service4.10%RXBioSyent33.65%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHCipher Pharmaceuticals517.95 millionN/ANot OptionableHEXOHEXO1,27744.00 million41.93 millionOptionableNINENine Energy Service94042.35 million39.74 millionOptionableRXBioSyentN/A11.44 millionN/ANot OptionableCPH, HEXO, NINE, and RX HeadlinesRecent News About These CompaniesBioSyent (CVE:RX) Shares Cross Below 50-Day Moving Average - Here's What HappenedApril 24, 2025 | marketbeat.comCould The Market Be Wrong About BioSyent Inc. (CVE:RX) Given Its Attractive Financial Prospects?April 18, 2025 | finance.yahoo.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Tenth Consecutive YearApril 1, 2025 | markets.businessinsider.comFAX Capital Corp. Sells 112,400 Shares of BioSyent Inc. (CVE:RX) StockDecember 24, 2024 | insidertrades.comInvesting in BioSyent (CVE:RX) five years ago would have delivered you a 110% gainDecember 15, 2024 | uk.finance.yahoo.comBioSyent Inc. (CVE:RX) Senior Officer Sells C$55,628.75 in StockDecember 13, 2024 | insidertrades.comInsider Selling: BioSyent Inc. (CVE:RX) Insider Sells 65,000 Shares of StockNovember 27, 2024 | insidertrades.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 230,800 SharesNovember 26, 2024 | insidertrades.comBioSyent Inc. (RX.V)November 25, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Will Pay A CA$0.045 Dividend In Four DaysNovember 24, 2024 | finance.yahoo.comCalculating The Fair Value Of BioSyent Inc. (CVE:RX)November 22, 2024 | finance.yahoo.comBioSyent Inc. (BIOYF)November 21, 2024 | finance.yahoo.comBioSyent Inc.November 13, 2024 | wsj.comAMD RDNA 4: everything we know so far about the RX 8000 seriesNovember 1, 2024 | digitaltrends.comBioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?October 24, 2024 | finance.yahoo.comSaatva Rx Mattress Review 2024: A Luxury Bed Designed for People With Chronic Health ConditionsOctober 1, 2024 | cnet.comShould You Be Adding BioSyent (CVE:RX) To Your Watchlist Today?September 26, 2024 | finance.yahoo.comInsider Selling: BioSyent Inc. (CVE:RX) Director Sells 2,320 Shares of StockSeptember 24, 2024 | insidertrades.comBioSyent Announces Agreement to Purchase Tibelia® (tibolone) AssetsSeptember 20, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 500,000 SharesSeptember 4, 2024 | insidertrades.comBioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045August 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPH, HEXO, NINE, and RX Company DescriptionsCipher Pharmaceuticals TSE:CPHC$13.20 -0.71 (-5.10%) As of 04:00 PM EasternCipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, and Out-Licensed Products among others. The company's geographical segments include Canada and the United States.HEXO NYSE:HEXOHEXO Corp., together with its subsidiaries, produces, markets, and sells cannabis in Canada. The company offers its adult-use and medical products under the HEXO brand name. It also provides cannabis beverages under the Little Victory, House of Terpenes, Mollo, Veryvell, and XMG brands; and cannabis products under UP Cannabis, Original Stash, and Up brand names. It has a strategic alliance with Tilray Brands, Inc. The company was formerly known as The Hydropothecary Corporation and changed its name to HEXO Corp. in August 2018. HEXO Corp. was founded in 2013 and is headquartered in Gatineau, Canada. As of June 22, 2023, HEXO Corp. operates as a subsidiary of Tilray Brands, Inc.Nine Energy Service NYSE:NINE$0.70 +0.02 (+2.87%) Closing price 03:59 PM EasternExtended Trading$0.70 +0.00 (+0.14%) As of 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nine Energy Service, Inc. operates as an onshore completion services provider that targets unconventional oil and gas resource development in North American basins and internationally. It offers cementing services, including blending high-grade cement and water with various solid and liquid additives to create a cement slurry that is pumped between the casing and the wellbore of the well. The company also provides open hole and cemented completion tool products, such as liner hangers and accessories, fracture isolation packers, frac sleeves, stage one prep tools, casing flotation tools, specialty open hole float equipment, disk subs, composite cement retainers, and centralizers that provide pinpoint frac sleeve system technologies. In addition, it offers wireline services consisting of plug-and-perf completions, which is a multistage well completion technique for cased-hole wells that consists of deploying perforating guns and isolation tools to a specified depth; and coiled tubing services, which perform wellbore intervention operations utilizing a continuous steel pipe that is transported to the wellsite wound on a large spool. The company was formerly known as NSC-Tripoint, Inc. and changed its name to Nine Energy Service, Inc. in October 2011. Nine Energy Service, Inc. was incorporated in 2011 and is headquartered in Houston, Texas.BioSyent CVE:RXC$10.88 +0.03 (+0.28%) As of 02:07 PM EasternBioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
